Spectrum Pharmaceuticals, Inc.

NasdaqCM:SPPI Stock Report

Market Cap: US$209.9m

Spectrum Pharmaceuticals Future Growth

Future criteria checks 5/6

Spectrum Pharmaceuticals is forecast to grow earnings and revenue by 67.3% and 35.5% per annum respectively while EPS is expected to grow by 75.4% per annum.

Key information

67.3%

Earnings growth rate

75.4%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate35.5%
Future return on equityn/a
Analyst coverage

Low

Last updated25 Jul 2023

Recent future growth updates

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12
Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Recent updates

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

May 14
Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12
Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Sep 20

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Sep 16
Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Sep 09

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Aug 21

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Jun 04
Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals: Some Last Words

Feb 25

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Oct 05
Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

Aug 12

Spectrum's Big Approval: Any Day Now

Jul 29

FDA initiates pre-approval inspection for Spectrum pharmaceuticals' ROLONTIS

Jun 01

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

May 31
Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Feb 12
We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Spectrum Pharma drops after announcing less-than-favorable Phase 2 data

Dec 22

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Dec 21
Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Spectrum Pharma Is Down But Not Out

Nov 16

Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib

Nov 11

Earnings and Revenue Growth Forecasts

NasdaqCM:SPPI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202520197361414
12/31/20241271418365
12/31/202373-18-2123
3/31/202326-68-88-88N/A
12/31/202210-78-97-97N/A
9/30/2022N/A-106-102-102N/A
6/30/2022N/A-117-109-109N/A
3/31/2022N/A-138-115-115N/A
12/31/2021N/A-158-120-119N/A
9/30/2021N/A-169-121-122N/A
6/30/2021N/A-184-127-125N/A
3/31/2021N/A-166-127-123N/A
12/31/2020N/A-171-127-122N/A
9/30/2020N/A-162-127-120N/A
6/30/2020N/A-140-131-119N/A
3/31/2020N/A-136-138-128N/A
12/31/2019N/A-135-144-135N/A
9/30/2019N/A-148-127-116N/A
6/30/2019N/A-191-103-100N/A
3/31/2019N/A-147-79-76N/A
12/31/2018N/A-127-65-62N/A
9/30/201829-102-63-63N/A
6/30/201865-51-59-59N/A
3/31/201899-87-46-45N/A
12/31/2017N/A-101-39-39N/A
9/30/2017135-81-30-29N/A
6/30/2017132-81-36-36N/A
3/31/2017132-84-54-54N/A
12/31/2016146-70N/A-40N/A
9/30/2016162-55N/A-34N/A
6/30/2016157-56N/A-30N/A
3/31/2016168-35N/A5N/A
12/31/2015163-53N/A7N/A
9/30/2015164-50N/A15N/A
6/30/2015183-42N/A34N/A
3/31/2015185-44N/A31N/A
12/31/2014187-46N/A-4N/A
9/30/2014176-82N/A-7N/A
6/30/2014171-78N/A-30N/A
3/31/2014157-84N/A-64N/A
12/31/2013156-62N/A-2N/A
9/30/2013184-15N/A-2N/A
6/30/201321114N/A30N/A
3/31/201324742N/A67N/A
12/31/201226894N/A72N/A
9/30/201225195N/A75N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SPPI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: SPPI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SPPI is expected to become profitable in the next 3 years.

Revenue vs Market: SPPI's revenue (35.5% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: SPPI's revenue (35.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SPPI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/02 23:25
End of Day Share Price 2023/07/31 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Spectrum Pharmaceuticals, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAuriga USA LLC
David BuckB. Riley Securities, Inc.
Alethia YoungCantor Fitzgerald & Co.